We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Draft Guidance on Quality-Related Controlled Correspondence
FDA Issues Draft Guidance on Quality-Related Controlled Correspondence
The FDA is responding to frequently asked questions from generic drugmakers — including sponsors of drug-device combination products — on quality-related control correspondence with the agency in a draft guidance released yesterday.